BioAtla initiated with a Buy at EF Hutton

EF Hutton analyst Tony Butler initiated coverage of BioAtla with a Buy rating and $25 price target. BioAtla is a clinical-stage biopharmaceutical company developing "conditionally active antibodies" to treat solid tumors, Butler tells investors in a research note. The analyst says the platform allows for the development of reversibly active therapies having an improved therapeutic index.